Jeff Heiser is the Chief Scientific Officer (CSO) of Microbial and Advanced Therapeutic Platforms at Boston Analytical. After graduating from the University of New Hampshire with a degree in Microbiology Research in 2007, he entered the industry working for Pfizer...

Chathurika Rathnayake, Ph. D., is the Manager of Analytical Development at Boston Analytical, Inc. in Salem, NH. She has been with Boston Analytical since 2019, serving first as a Senior Scientist, then as Group Leader, and now in her current role. She oversees a...

SALEM, New Hampshire - Boston Analytical, a leading provider of analytical and microbiological testing to the pharmaceutical, biopharmaceutical, and medical device industries is pleased to announce that their most recent FDA inspection resulted in no 483 observations....

Nitrosamine Drug Substance-Related Impurity Testing Ensuring that drug products do not contain nitrosamine compounds is vitally important given their toxicity. Nitrosamines can only form under certain conditions (luckily), however their high toxicity predicates the...

Mark comes to Boston Analytical with 16+ years of experience working in the pharmaceutical industry. He currently is the Director of Analytical Development at Boston Analytical. Previously Mark was a Senior Group Leader managing all analytical method...

Karina has been with Boston Analytical since 2017 and is the Director and Principal Scientist in the Biological Macromolecules Laboratory. In addition, Karina has had previous experience researching and developing methods in our Analytical Development Laboratory. She...